Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management

Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management (December 2019)

Friday, December 6, 2019
Webinar -- 6:30 PM ET

Agenda

Welcome and Introduction

Overview of the BCR Pathway and BTK in Tumor Development 

Safety and Efficacy of BTK inhibitors in The Management of B-Cell Malignancies

Practical Case Discussions: Selecting BTK inhibitor Therapy in B-Cell Malignancies

Overcoming BTK Inhibitor Resistance and Combination Strategies

Final Thoughts and Audience Question and Answer Session

Faculty

Faculty
Jan A. Burger, MD, PhD

Professor of Medicine
Department of Leukemia, Unit 428
The University of Texas MD Anderson Cancer Center
Houston, TX

Faculty
Ian W. Flinn, MD, PhD

Director, Lymphoma Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Faculty
John Pagel, MD, PhD

Chief of Hematologic Malignancies
Swedish Cancer Institute
Seattle, Washington

Faculty
Laurie H. Sehn, MD, MPH

Chair, Lymphoma Tumour Group
Associate Editor, Blood
BC Cancer
Vancouver, BC

Goal Statement
The goal of this activity is to improve participants’ knowledge of and competence in selecting and safely integrating BTK inhibitors within the current treatment paradigm for various B-cell malignancies considering patient-specific and prognostic factors as well as appropriate dosing and strategies to manage treatment-emergent adverse events.

Target Audience
This program is intended for hematologists, hematologist-oncologists, and other clinicians involved in the management of patients with MCL, CLL, and other B-cell malignancies.

Learning Objectives

  • Evaluate differences among agents targeting BTK in terms of molecular characteristics, preclinical data, approved indications, dosing, safety profile, and efficacy
  • Plan optimal, individualized therapeutic strategies for patients with MCL, CLL/SLL, WM and other B-cell malignancies taking into consideration recent practice-changing clinical trial results
  • Recognize and manage adverse events and toxicities associated with BTK inhibitor therapy to support adherence, appropriate dosing, quality of life, and continuation of treatment
  • Assess ongoing clinical trials evaluating currently available and emerging BTK inhibitors (and BTK-based combinations) to aid clinical trial enrollment and predict new options in the clinic

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.